Abstract
Abstract Antiphospholipid antibodies (aPL) may accompany a response to many infectious agents. The emergence of aPL may be transient or may be associated with the clinical picture of the antiphospholipid syndrome (APS) with manifestations including thrombosis, recurrent fetal loss, central nervous system (CNS), and other organ involvement. The most studied pathogenic aPL are directed to the β 2 glycoprotein I (β 2 GPI) molecule. Studies on experimental APS models have proved that molecular mimicry between β 2 GPI-related synthetic peptides and structures within bacteria, viruses, tetanus toxoid, and cytomegalovirus (CMV) can induce experimental APS. Any explanation of how microbial infections might set off APS must take into account the observation that all individuals appear to harbor potentially autoreactive lymphocytes, as well as natural aPL, but that these cells or antibodies remain innocuous unless somehow activated by a second hit. In this chapter we discuss the associations of aPL in infectious states, molecular mimicry as a proposed cause for the development of APS, aPL vaccination, and drug-induced aPL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.